Connect Biopharma's IL-4/IL-13 blocker cuts COPD exacerbations by 85% in Phase 2 trial
Connect Biopharma reported phase 2 results for its IL-4/IL-13 inhibitor rademikibart in COPD patients.
In the Seabreeze STAT study of 159 participants who had recent exacerbations, adding rademikibart to standard care lowered the primary endpoint-treatment failure within 28 days-by 81% compared with placebo, and reduced moderate-to-severe exacerbations by 85%.
The trial did not meet a secondary endpoint measuring post-bronchodilator FEV1 after seven days, although a 70 mL improvement at week 4 was described as clinically meaningful.
The results suggest the drug may offer a new anti-inflammatory option for COPD, but further studies will be needed to confirm lung-function benefits.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that